Jane Street
ADAP

Jane Street’s Adaptimmune Therapeutics ADAP Stock Holding History

Jane Street’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-23,600
Closed -$122K – 9973
2021
Q3 		$122K Buy
+23,600
New +$106K ﹤0.01% 9187
2021
Q2 		– Sell
-16,200
Closed -$86K – 9692
2021
Q1 		$86K Sell
16,200
-49,900
-75% -$286K ﹤0.01% 8690
2020
Q4 		$356K Buy
+66,100
New +$359K ﹤0.01% 6180
2020
Q3 		– Sell
-28,800
Closed -$288K – 7072
2020
Q2 		$288K Buy
+28,800
New +$181K ﹤0.01% 5898

Other funds holding ADAP

JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
EF
Empirical Finance Havertown, Pennsylvania $2.13B AUM 29.56% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Jane Street's ADAP Position: Q4 2025 in Review

Jane Street sold out of Adaptimmune Therapeutics (ADAP) in Q4 2025, closing a stake of 2,805,345 shares — an estimated $365K sold.

Jane Street first reported a position in ADAP in Q1 2018 and held it in 12 quarters. The position peaked at $365K in Q3 2025. 10 funds tracked by Wall St. Rank hold ADAP as of Q4 2025.

  • Jane Street reported no remaining Adaptimmune Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Jane Street sold 2,805,345 Adaptimmune Therapeutics shares in Q4 2025, an estimated $365K.
  • Jane Street first reported a position in Adaptimmune Therapeutics in Q1 2018 and held it in 12 quarters.
  • Jane Street's Adaptimmune Therapeutics position peaked at $365K in Q3 2025.
  • 10 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2025.

Based on Jane Street's 13F filing for Q4 2025, filed 12 Feb 2026.